朋友或敌人:在NSTEMI的管理过程中偶然发现了XII因子缺乏
Patrick J Beck1, John Benfield1,2, Joshua Morales1,2,3
1Virginia Tech Carilion School of Medicine, 2 Riverside Circle, Roanoke, VA 24016, USA.
第十二因子 (FXII) 缺乏,一种罕见的出血障碍,往往没有被注意到. 这一案例凸显了FXII缺乏如何使急性冠状动脉综合征 (ACS) 的抗凝管理复杂化.
科学领域:
- 血液学 血液学 血液学
- 心脏病学 心脏病学
背景情况:
- 十二因子 (FXII) 缺乏症是一种罕见的遗传性出血障碍.
- 它通常无症状,导致诊断延迟.
- 长时间激活的部分血栓形成时间 (aPTT) 是一个关键指标.
更多相关视频
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
10:01Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
Published on: March 12, 2018
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
